| DC Field | Value | Language |
|---|
| dc.contributor.author | Eleskina, A. A. | - |
| dc.contributor.author | Pyatigorskaya, N. V. | - |
| dc.contributor.author | Filippova, O. V. | - |
| dc.date.accessioned | 2023-10-03T09:38:57Z | - |
| dc.date.available | 2023-10-03T09:38:57Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.citation | Eleskina, A.A. Impact of COVID-19 on clinical trials protocol amendments / A.A. Eleskina, N.V. Pyatigorskaya, O.V. Filippova // Research Results in Pharmacology. - 2023. - Vol.9, №2.-P. 11-15. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/56826 | - |
| dc.description.abstract | The COVID-19 pandemic situation had a great impact on all spheres of people’s lives. It also affected clinical trials as Sponsors, sites and investigators faced a number of problems, such as systematic IMP taking, adherence to protocol visits, efficacy evaluations, laboratory procedures, and analyses | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | COVID-19 | ru |
| dc.subject | clinical trials | ru |
| dc.subject | pandemic 2020 | ru |
| dc.subject | protocol amendments | ru |
| dc.title | Impact of COVID-19 on clinical trials protocol amendments | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 9, № 2
|
